David A Solomon

List of Publications by Year
in descending order

122 papers	6,046 citations	76196 40 h-index	82410 72 g-index
126 all docs	126 docs citations	126 times ranked	9317 citing authors

#	Article	IF	Citations
1	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine, 2014, 20, 1394-1396.	15.2	411
2	Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer. Science, 2011, 333, 1039-1043.	6.0	397
3	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	2.1	363
4	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. PLoS Genetics, 2014, 10, e1004475.	1.5	335
5	Diffuse Midline Gliomas with Histone <scp>H3â€K27M</scp> Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain Pathology, 2016, 26, 569-580.	2.1	334
6	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
7	Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics, 2013, 45, 1428-1430.	9.4	164
8	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
9	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology, 2017, 19, now254.	0.6	155
10	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. American Journal of Neuroradiology, 2017, 38, 795-800.	1.2	132
11	The genetic landscape of ganglioglioma. Acta Neuropathologica Communications, 2018, 6, 47.	2.4	130
12	Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma. Cancer Research, 2008, 68, 10300-10306.	0.4	114
13	Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Modern Pathology, 2017, 30, 246-254.	2.9	95
14	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nature Genetics, 2022, 54, 649-659.	9.4	93
15	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology, 2019, 29, 85-96.	2.1	88
16	Characterization of gliomas: from morphology to molecules. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 257-269.	1.4	86
17	A pilot precision medicine trial for children with diffuse intrinsic pontine gliomaâ€"PNOC003: A report from the Pacific Pediatric Neuroâ€Oncology Consortium. International Journal of Cancer, 2019, 145, 1889-1901.	2.3	84
18	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Modern Pathology, 2018, 31, 660-673.	2.9	76

#	Article	IF	Citations
19	Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Modern Pathology, 2019, 32, 88-99.	2.9	76
20	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro-Oncology, 2021, 23, 34-43.	0.6	75
21	Highâ€grade neuroepithelial tumor with BCOR exon 15 internal tandem duplicationâ€"a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathology, 2020, 30, 46-62.	2.1	69
22	STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection. Nature Communications, 2018, 9, 1485.	5.8	68
23	Clinicopathologic Features of a Second Patient With Ewing-like Sarcoma Harboring CIC-FOXO4 Gene Fusion. American Journal of Surgical Pathology, 2014, 38, 1724-1725.	2.1	67
24	Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nature Communications, 2018, 9, 1894.	5.8	65
25	A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nature Communications, 2019, 10, 1686.	5.8	65
26	Dynamic targeting of the replication machinery to sites of DNA damage. Journal of Cell Biology, 2004, 166, 455-463.	2.3	63
27	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Modern Pathology, 2017, 30, 1086-1099.	2.9	63
28	The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica, 2019, 137, 139-150.	3.9	57
29	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications, 2018, 9, 810.	5.8	56
30	Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathology, 2018, 28, 192-202.	2.1	56
31	Correlation of exon 3 Î²-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Modern Pathology, 2016, 29, 1370-1380.	2.9	55
32	Cohesin gene mutations in tumorigenesis: from discovery to clinical significance. BMB Reports, 2014, 47, 299-310.	1.1	55
33	Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathologica, 2018, 135, 485-488.	3.9	54
34	Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro-Oncology, 2017, 19, 78-88.	0.6	51
35	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathologica, 2019, 137, 521-525.	3.9	51
36	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathologica, 2020, 139, 1071-1088.	3.9	50

#	Article	IF	Citations
37	Identification of p18INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme. Cancer Research, 2008, 68, 2564-2569.	0.4	48
38	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro-Oncology, 2021, 23, 1872-1884.	0.6	48
39	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Modern Pathology, 2018, 31, 141-149.	2.9	47
40	Myxoid glioneuronal tumor, PDGFRA p.K385â€mutant: clinical, radiologic, and histopathologic features. Brain Pathology, 2020, 30, 479-494.	2.1	46
41	Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathologica, 2019, 137, 851-854.	3.9	45
42	Intracranial mesenchymal tumor with FETâ€CREB fusionâ€”A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytomaâ€like neoplasms. Brain Pathology, 2021, 31, e12918.	2.1	44
43	Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathologica Communications, 2017, 5, 38.	2.4	41
44	Conspirators in a Capital Crime: Co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in Glioblastoma Multiforme: Figure 1.. Cancer Research, 2008, 68, 8657-8660.	0.4	40
45	Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features. Ophthalmology, 2020, 127, 804-813.	2.5	39
46	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathologica, 2018, 136, 339-343.	3.9	37
47	The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. Journal of Neuro-Oncology, 2017, 132, 1-11.	1.4	35
48	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathologica Communications, 2020, 8, 151.	2.4	35
49	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncology Advances, 2020, 2, vdaa142.	0.4	35
50	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 632-641.	0.6	33
51	<scp>CRTC</scp>1â€“<scp>MAML</scp>2 fusion in mucoepidermoid carcinoma of the breast. Histopathology, 2019, 74, 463-473.	1.6	33
52	Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathologica, 2016, 132, 757-760.	3.9	32
53	Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. , 2017, 36, 213-221.		32
54	Sample Type Bias in the Analysis of Cancer Genomes. Cancer Research, 2009, 69, 5630-5633.	0.4	29

#	Article	IF	Citations
55	RecurrentEP300-BCORFusions in Pediatric Gliomas With Distinct Clinicopathologic Features. Journal of Neuropathology and Experimental Neurology, 2019, 78, 305-314.	0.9	29
56	Hemosiderotic Fibrolipomatous Tumor, Not an Entirely Benign Entity. American Journal of Surgical Pathology, 2013, 37, 1627-1630.	2.1	27
57	Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. American Journal of Neuroradiology, 2019, 40, 1804-1810.	1.2	27
58	Clinicopathologic features of anaplastic myxopapillary ependymomas. Brain Pathology, 2019, 29, 75-84.	2.1	25
59	Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components. Modern Pathology, 2020, 33, 1193-1206.	2.9	25
60	ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system. Acta Neuropathologica, 2019, 138, 335-337.	3.9	24
61	Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. Acta Neuropathologica, 2017, 134, 671-673.	3.9	22
62	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.0	22
63	Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	22
64	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica, 2019, 138, 877-881.	3.9	21
65	IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10Âyears of age. Acta Neuropathologica, 2016, 132, 153-155.	3.9	20
66	InactivatingMUTYHgermline mutations in pediatric patients with high-grade midline gliomas. Neuro-Oncology, 2016, 18, 752-753.	0.6	20
67	Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. Brain Pathology, 2020, 30, 213-225.	2.1	20
68	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 2021, 27, 6197-6208.	3.2	20
69	A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection. Neurosurgery, 2021, 88, 202-210.	0.6	19
70	Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Future Oncology, 2016, 12, 1493-1506.	1.1	18
71	Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. Acta Neuropathologica, 2020, 139, 953-957.	3.9	18
72	Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathologica, 2017, 134, 961-963.	3.9	17

#	Article	IF	Citations
73	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	3.9	17
74	Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to â€˜Polymorphous low-grade neuroepithelial tumor of the youngâ€™. Acta Neuropathologica, 2021, 142, 595-599.	3.9	16
75	CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. Clinical Cancer Research, 2022, 28, 2898-2910.	3.2	16
76	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology, 2022, 24, 1471-1481.	0.6	14
77	Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathologica Communications, 2018, 6, 95.	2.4	13
78	The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. Acta Neuropathologica, 2020, 140, 907-917.	3.9	13
79	A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma. Journal of Neurosurgery: Spine, 2021, 35, 834-843.	0.9	13
80	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica, 2022, 143, 403-414.	3.9	13
81	Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. Journal of Neuro-Oncology, 2019, 143, 137-144.	1.4	12
82	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro-Oncology, 2021, 23, 1974-1976.	0.6	12
83	Pancreatic involvement by mesenchymal chondrosarcoma harboring the HEY1-NCOA2 gene fusion. Human Pathology, 2016, 58, 35-40.	1.1	11
84	Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathologica, 2017, 133, 661-663.	3.9	11
85	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathologica, 2022, 143, 109-113.	3.9	11
86	Intracranial mesenchymal tumors with FETâ€CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathology, 2022, 32, e13037.	2.1	11
87	Chordoid glioma of the third ventricle: report of a rapidly progressive case. Journal of Neuro-Oncology, 2017, 132, 487-495.	1.4	10
88	Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging. Neuro-Oncology Practice, 2018, 5, 234-240.	1.0	10
89	Pathology of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 87-99.	1.0	10
90	DNA methylation profiling demonstrates superior diagnostic classification to RNA-sequencing in a case of metastatic meningioma. Acta Neuropathologica Communications, 2020, 8, 82.	2.4	10

#	Article	IF	Citations
91	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	0.6	10
92	Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathologica, 2022, 144, 579-583.	3.9	10
93	Uveal Ganglioneuroma due to Germline <i>PTEN</i> Mutation (Cowden) Tj ETQq1 1 0.784314 rgBT /Ov 122-128.	0.5	9
94	Loss of H3K27 trimethylation by immunohistochemistry is frequent in oligodendroglioma, IDH-mutant and 1p/19q-codeleted, but is neither a sensitive nor a specific marker. Acta Neuropathologica, 2020, 139, 597-600.	3.9	9
95	A case of recurrent epilepsyâ€associated rosetteâ€forming glioneuronal tumor with anaplastic transformation in the absence of therapy. Neuropathology, 2019, 39, 389-393.	0.7	8
96	Preoperative MR Imaging to Differentiate Chordoid Meningiomas from Other Meningioma Histologic Subtypes. American Journal of Neuroradiology, 2019, 40, 433-439.	1.2	8
97	A review of recently described genetic alterations in central nervous system tumors. Human Pathology, 2020, 96, 56-66.	1.1	8
98	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	3.9	7
99	A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances, 2022, 6, 3189-3193.	2.5	7
100	Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 2022, 144, 373-376.	3.9	7
101	Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric Blood and Cancer, 2017, 64, e26708.	0.8	6
102	Familial Tumor Syndromes. , 2018, , 505-545.		5
103	Loss of ZNF750 in ocular and cutaneous sebaceous carcinoma. Journal of Cutaneous Pathology, 2019, 46, 736-741.	0.7	5
104	A novel PARD3B-NUTM1 fusion in an aggressive primary CNS embryonal tumor in a young adult. Acta Neuropathologica Communications, 2020, 8, 112.	2.4	5
105	Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma. Acta Neuropathologica, 2022, 143, 283-286.	3.9	5
106	Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. Journal of Neuropathology and Experimental Neurology, 2022, 81, 650-657.	0.9	5
107	An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion. Acta Neuropathologica Communications, 2019, 7, 110.	2.4	4
108	HGG-15. SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR. Neuro-Oncology, 2019, 21, ii89-ii90.	0.6	4

#	Article	IF	Citations
109	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. BMC Neurology, 2020, 20, 106.	0.8	4
110	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	0.9	4
111	Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers. Journal of Pediatric Hematology/Oncology, 2021, 43, e987-e990.	0.3	4
112	Aneurysm of the Posterior Meningeal Artery Embedded Within a Dorsal Exophytic Medullary Hemangioblastoma: Surgical Management and Review of Literature. Journal of Cerebrovascular and Endovascular Neurosurgery, 2014, 16, 293.	0.2	3
113	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippelâ€“Lindau diseaseâ€related tumours. Neuropathology and Applied Neurobiology, 2021, 47, 756-767.	1.8	2
114	Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia. Neuro-Oncology, 2021, 23, 1798-1800.	0.6	2
115	ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	0.6	2
116	Neuroglial stem cell-derived inflammatory pseudotumor (n-SCIPT): clinicopathologic characterization of a novel lesion of the lumbosacral spinal cord and nerve roots following intrathecal allogeneic stem cell intervention. Acta Neuropathologica, 2019, 138, 1103-1106.	3.9	1
117	Eye-sparing Treatment of Localized Orbital Medulloepithelioma With Neoadjuvant Chemoradiation. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, e13-e16.	0.4	1
118	OTHR-41. Amplification of the PLAG family genes â€“ PLAGL1 and PLAGL2 â€“ is a key feature of a novel embryonal CNS tumor type. Neuro-Oncology, 2022, 24, i156-i156.	0.6	1
119	Cell of the month: Heterochromatic domains in a mouse nucleus. Nature Cell Biology, 2004, 6, 295-295.	4.6	0
120	An update on the central nervous system manifestations of familial tumor predisposition syndromes. Acta Neuropathologica, 2020, 139, 609-612.	3.9	0
121	Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease. International Journal of Hematology-Oncology and Stem Cell Research, 2021, 15, 260-264.	0.3	0
122	EPEN-07. PATTERNS OF EXTRANEURAL METASTASES IN PEDIATRIC SUPRATENTORIAL EPENDYMOMA: CASE SERIES AND REVIEW OF THE LITERATURE. Neuro-Oncology, 2020, 22, iii309-iii309.	0.6	0